-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Maintains Buy on Rhythm Pharmaceuticals, Lowers Price Target to $114

Benzinga·11/03/2026 19:54:57
Listen to the news
Needham analyst Joseph Stringer maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and lowers the price target from $130 to $114.